U.S. Health Secretary Robert F. Kennedy Jr. reignited vaccine controversy this week by repeating debunked claims about the MMR (Measles, Mumps, Rubella) vaccine during a growing measles outbreak, one of the worst in 25 years. Kennedy alleged that the vaccine contains cells from aborted fetuses and questioned the efficacy of the mumps component, sparking backlash from medical experts.
The outbreak, centered in a Mennonite community in Texas, has spread to Oklahoma, Kansas, and New Mexico, infecting hundreds and killing two children. Scientists warn the U.S. may lose its measles elimination status, achieved in 2000, if vaccination rates continue to decline.
Kennedy, long known for promoting vaccine skepticism, claimed in a News Nation interview that religious groups avoid the MMR vaccine due to "aborted fetus debris." However, experts clarified that while the rubella component is produced using a fetal cell line from a 1960s abortion, no actual fetal cells are present in the final vaccine. These lab-grown cells have been replicated for decades and are filtered out during production, leaving only a purified, weakened virus.
According to Dr. Miriam Laufer from the University of Maryland and Dr. Paulo Verardi from the University of Connecticut, any DNA remnants in the final vaccine are negligible—measured in billionths of a gram.
Kennedy also said the mumps portion of the vaccine “doesn’t work” and lacked proper safety testing. However, the CDC reports that two doses of MMR provide about 86% protection against mumps. While immunity may wane over time, vaccinated individuals typically experience milder symptoms if infected.
The Department of Health and Human Services declined to comment on Kennedy’s statements, which many experts say undermine public trust in proven vaccine science.


FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates
Zelenskiy Signals Willingness to Drop NATO Bid as Ukraine, U.S. Hold Crucial Peace Talks in Berlin
U.S. Suspends UK Technology Deal Amid Trade Disputes Under Trump Administration
Thousands Protest in Brazil Against Efforts to Reduce Jair Bolsonaro’s Prison Sentence
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership
Special Prosecutor Alleges Yoon Suk Yeol Sought North Korea Provocation to Justify Martial Law
Sydney Bondi Beach Terror Attack Kills 16, Sparks Gun Law and Security Debate
U.S. Reveals 2026 Medicare Star Ratings: Aetna, UnitedHealth Lead in Quality Scores
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage
Belarus Frees Opposition Leaders Maria Kalesnikava and Viktar Babaryka in U.S.-Brokered Deal
U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance
Ukraine’s NATO Concession Unlikely to Shift Peace Talks, Experts Say
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025
Pfizer Secures $10 Billion Deal for Obesity Drug Developer Metsera, Outbids Novo Nordisk
Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence 



